63.83
CRISPR Therapeutics AG stock is currently priced at $63.83, with a 24-hour trading volume of 863.18K.
It has seen a -2.24% decreased in the last 24 hours and a +14.52% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $66.01 pivot point. If it approaches the $63.03 support level, significant changes may occur.
Previous Close:
$65.26
Open:
$64.78
24h Volume:
863.18K
Market Cap:
$5.40B
Revenue:
$170.10M
Net Income/Loss:
$-153.61M
P/E Ratio:
-14.28
EPS:
-4.47
Net Cash Flow:
$-272.35M
1W Performance:
+10.25%
1M Performance:
+14.52%
6M Performance:
+1.37%
1Y Performance:
+8.21%
CRISPR Therapeutics AG Stock (CRSP) Company Profile
Name
CRISPR Therapeutics AG
Sector
Industry
Phone
41 41 561 3277
Address
Baarerstrasse 14, Zug
CRISPR Therapeutics AG Stock (CRSP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
Dec-11-23 | Downgrade | TD Cowen | Market Perform → Underperform |
Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Sep-27-23 | Initiated | Mizuho | Buy |
Aug-17-23 | Upgrade | Citigroup | Neutral → Buy |
May-30-23 | Initiated | William Blair | Outperform |
Apr-13-23 | Initiated | Cantor Fitzgerald | Overweight |
Mar-21-23 | Initiated | Bernstein | Mkt Perform |
Mar-17-23 | Initiated | Bryan Garnier | Buy |
Mar-07-23 | Initiated | Robert W. Baird | Neutral |
Oct-11-22 | Initiated | Morgan Stanley | Underweight |
Aug-09-22 | Downgrade | Barclays | Overweight → Equal Weight |
Jun-23-22 | Downgrade | Evercore ISI | Outperform → In-line |
Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
Apr-28-22 | Initiated | Credit Suisse | Neutral |
Dec-07-21 | Initiated | Cowen | Market Perform |
Oct-19-21 | Initiated | SVB Leerink | Outperform |
Jun-14-21 | Upgrade | Citigroup | Sell → Neutral |
Apr-21-21 | Upgrade | Jefferies | Hold → Buy |
Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
Dec-10-20 | Reiterated | Chardan Capital Markets | Buy |
Dec-10-20 | Downgrade | Jefferies | Buy → Hold |
Dec-10-20 | Reiterated | Needham | Buy |
Dec-07-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
Oct-05-20 | Initiated | BofA Securities | Buy |
Jul-28-20 | Reiterated | Needham | Buy |
Jul-14-20 | Initiated | SunTrust | Buy |
Jun-15-20 | Reiterated | Canaccord Genuity | Buy |
Mar-05-20 | Initiated | Stifel | Hold |
Feb-03-20 | Downgrade | Evercore ISI | Outperform → In-line |
Nov-19-19 | Upgrade | William Blair | Mkt Perform → Outperform |
Nov-12-19 | Upgrade | Oppenheimer | Perform → Outperform |
Aug-01-19 | Initiated | Jefferies | Buy |
Jul-26-19 | Initiated | Canaccord Genuity | Buy |
Jun-10-19 | Initiated | ROTH Capital | Buy |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Mar-14-19 | Initiated | William Blair | Mkt Perform |
Jan-28-19 | Downgrade | Goldman | Buy → Neutral |
Jan-22-19 | Downgrade | Citigroup | Neutral → Sell |
View All
CRISPR Therapeutics AG Stock (CRSP) Latest News
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Yahoo Finance
C M Bidwell & Associates Ltd. Lowers Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
Defense World
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 5.9% - MarketBeat
MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 1.7% - MarketBeat
MarketBeat
25065 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Bought by Nebula Research & Development LLC - MarketBeat
MarketBeat
CRISPR Therapeutics (CRSP) Presents at Goldman Sachs 45th Annual Global Healthcare Conference - Company Call ... - Seeking Alpha
Seeking Alpha
CRISPR Therapeutics AG Stock (CRSP) Financials Data
CRISPR Therapeutics AG (CRSP) Revenue 2024
CRSP reported a revenue (TTM) of $170.10 million for the quarter ending June 30, 2023, a +1,207% rise year-over-year.
CRISPR Therapeutics AG (CRSP) Net Income 2024
CRSP net income (TTM) was -$153.61 million for the quarter ending December 31, 2023, a +76.37% increase year-over-year.
CRISPR Therapeutics AG (CRSP) Cash Flow 2024
CRSP recorded a free cash flow (TTM) of -$272.35 million for the quarter ending December 31, 2023, a +48.90% increase year-over-year.
CRISPR Therapeutics AG (CRSP) Earnings per Share 2024
CRSP earnings per share (TTM) was -$1.93 for the quarter ending December 31, 2023, a +76.94% growth year-over-year.
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; and with the ViaCyte, Inc. for designing allogeneic cell therapies derived from gene edited human stem cells for use in the treatment of diabetes type 1, diabetes type 2, and insulin dependent diabetes. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Cap:
|
Volume (24h):